Abdullah Esmail^1,*, Waseem Abdelrahim², Ebtesam Al-Najjar¹, Raed Zaidan³, Tahrir Abdelrahim¹

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.083192 - 16 July 2026

Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is frequently diagnosed at an advanced stage and remains associated with poor survival outcomes. Durable responses to systemic therapy in metastatic disease are uncommon. We report a case of metastatic PDAC with prolonged survival and sustained response following first-line treatment with NALIRIFOX. This report describes a patient with metastatic PDAC who achieved prolonged disease control and sustained response following first-line treatment with NALIRIFOX. Case Presentation: A 64-year-old woman presented with abdominal pain, early satiety, weight loss, and markedly elevated CA 19-9 levels. Imaging demonstrated a pancreatic head… More >

Giovanni Leuzzi^1,*, Michele Ferrari¹, Federica Sabia¹, Alessandro Pardolesi¹, Alessia Stanzi¹, Claudia Proto², Giuseppe Lo Russo², Arsela Prelaj², Monica Ganzinelli², Matteo Calderoni¹, Clarissa Uslenghi¹, Ugo Pastorino³, Piergiorgio Solli¹

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.077158 - 16 July 2026

Abstract Backgrounds: Despite the availability of multimodal strategies, no universally accepted guidelines exist for the management of advanced Thymic Epithelial Tumors (TETs), particularly in locally advanced thymomas. The aim of this study was to evaluate the oncological and surgical outcomes of induction therapy (IT) followed by surgery in patients with Masaoka–Koga stage III–IVA TETs. To this end, we conducted a systematic review and meta-analysis assessing surgical-pathological and survival outcomes. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials was performed.… More > Graphic Abstract

Lorenzo Gasperoni^1,*, Luna Del Bono², Alberto Farolfi³, Andrea Messori^4,5, Vera Damuzzo^5,6

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.077700 - 16 June 2026

Abstract Background: Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are established maintenance treatments in ovarian cancer, but comparative efficacy across genetic profiles and relapse risk categories remains unclear. The aim of this study was to compare the efficacy of different PARPi as maintenance therapy in ovarian cancer across genetic profiles and relapse risk categories using reconstructed individual patient data (IPD) from randomized trials (RCTs). Methods: IPD were reconstructed using the IPDfromKM method from published Kaplan-Meier curves of RCTs stratified by clinical risk subgroup. Progression-free survival (PFS) was the primary endpoint. Three comparisons were performed: Breast Cancer gene (BRCA)+… More >

Manal Mohammed AL-Tamimi^1,2,*, Siti Norul Huda Sheikh Abdullah^1,*, Mohammad Khatim Hasan¹, Mohammed Azmi Al-Betar^3,4, Maw Shin Sim⁵, Abdulrahman Mohammed AL-Tamimi¹

CMES-Computer Modeling in Engineering & Sciences, Vol.147, No.2, 2026, DOI:10.32604/cmes.2026.079891 - 27 May 2026

Abstract Pan-cancer survival prediction remains a major challenge in personalized oncology due to profound tumor heterogeneity and the complexity of high-dimensional molecular data. Diverse risk profiles across cancer types and noisy, sparse features hinder deep learning models from capturing robust prognostic patterns. Prior pan-cancer studies predominantly focus on multimodal integration or unimodal gene expression analysis, leaving other informative modalities such as Copy Number Variation (CNV) and miRNA expression underexplored. We introduce a new formulation of mixture-of-experts (MoE) survival modeling that recasts expert assignment as a clinically interpretable risk-space decomposition problem. The proposed framework, CoxGuided-SE, constructs an… More >

Eun-Jeong Jeong^1,2,#, Yeon Soo Kim^2,#, Yujin Lee³, Jae-Sung Ryu⁴, Yung Hyun Choi^5,6, Eunjeong Kim^3,7,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.078376 - 21 May 2026

Abstract Objective: The systematic evaluation of expansive genomic databases facilitates the discovery of clinically vital biomarkers. While Sideroflexin 3 (SFXN3) consistently displays elevated expression in head and neck squamous cell carcinoma (HNSCC), its specific pathobiological functions and prognostic value remain insufficiently characterized. This study aims to delineate the clinical and functional significance of SFXN3 in HNSCC. Methods: We interrogated SFXN3 expression patterns, patient survival outcomes, and immune cell infiltration characteristics utilizing multiple independent repositories, including the cancer genome atlas (TCGA) and gene expression omnibus (GEO). The prognostic independence of SFXN3 was verified via multivariate Cox regression. These… More > Graphic Abstract

Fang-Ying Chiu^1,2,3,*, Yun Yen^2,4,5,6

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.077076 - 21 May 2026

Abstract Objective: Glioblastoma (GBM) is the most common primary malignant brain tumor and is characterized by significant intratumoral heterogeneity. This study aimed to investigate the clinical and genomic landscapes of GBM across diverse ethnic populations to identify potential prognostic markers. Methods: Leveraging The Cancer Imaging Archive (TCIA) and bioinformatics modeling, White, African, and Asian American cohorts were analyzed. Patients were stratified according to the 2021 WHO classification of central nervous system (CNS) tumors. Population-specific genomic drivers and phenotypic markers were evaluated for their impact on outcomes. Survival rates across age, sex, and ethnicity were estimated using the… More >

Evangelos Manousakis¹, Cristina Moreta-Moraleda¹, Clàudia Martinez Miralles¹, Anna Tomàs Pujolà¹, Houda Baccara², Laia Liñán Franquet¹, Montserrat Montañés Albó¹, Roberto Ferrari², Roni H. G. Wright^1,*

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.074965 - 22 April 2026

Abstract Objective: Breast cancer remains one of the most prevalent malignancies among women worldwide, and despite advances in therapy and treatment options, tumour relapse and metastasis remain major clinical challenges, largely driven by the breast cancer stem cells (BCSCs) niche that resists conventional treatments and regenerates tumours. In breast cancer, where approximately 30% of patients who initially respond to treatment ultimately relapse and die of metastatic disease, targeting BCSCs is critical for improving patient outcomes. Cyclin-dependent kinase inhibitor 1A/p21 (CDKN1A/p21) is a multifunctional protein that is known primarily for its role in regulating the cell cycle… More > Graphic Abstract

Aleksander Strąk¹, Ludmiła Grzybowska-Szatkowska^1,*, Paweł Cisek¹, Marta Ostrowska-Leśko², Jarosław Dudka², Joanna Kubik³, Jacek Osuchowski⁴, Paweł Szmygin⁴, Bożena Jarosz⁴, Andrzej Krajka⁵, Tomasz Krajka⁶, Kazimierz Szatkowski⁷, Brygida Ślaska⁸

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.074078 - 22 April 2026

Abstract Objectives: Brain gliomas are among the tumors with the worst prognosis, and their incidence is increasing. Postoperative temozolomide-based chemoradiotherapy for grades 3 and 4 gliomas extended overall survival (OS) by approximately two months. An increasing number of clinical trials are investigating molecular-based therapy. Recent studies have demonstrated the involvement of Golgi apparatus proteins, including MYO18A (myosin-18A), in processes associated with abnormal proliferation, migration, apoptosis evasion, and angiogenesis promotion. The aim of this study was to investigate whether MYO18A has prognostic value in patients treated for brain gliomas. Methods: The research material in the work included… More >

Luigi Coltelli^1,2,#, Paola Orlandi^3,#, Chiara Finale^1,4,#, Gianna Musettini^1,4,#, Luna Chiara Masini^1,4, Marco Scalese⁵, Giulia Soria^1,4, Elena Sartori^1,4, Ylenia Nodari^1,4, Giada Arrighi^1,2, Arianna Bandini³, Marta Banchi³, Costanza Tacchi³, Donghao Tang³, Barbara Salvadori⁶, Lucia Tanganelli^1,7, Simona Giovannelli^1,8, Mirco Pistelli⁹, Samanta Cupini^1,4, Maurizio Lucchesi^1,10, Alessandro Cosimi¹¹, Giulia Lorenzini^1,7, Elisa Biasco^1,4, Chiara Caparello^1,4, Giulia Acconci^1,4,6, Eloise Fontana^1,4, Eleonora Bona^1,4, Azzurra Farnesi^1,4, Antonio Pellino^1,4, Andrea Marini^1,4, Ermelinda De Maio^1,4, Irene Stasi^1,4, Cecilia Barbara^1,4, Enrico Sammarco^1,4, Javier Rosada^12,13, Giacomo Allegrini^1,4,*, Guido Bocci^3,*

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.073799 - 22 April 2026

Abstract Background: The treatment of advanced hormone receptor-positive (HR+) breast cancer has seen relevant changes in last years. However, bevacizumab remains an option when combined with paclitaxel, but no certified pharmacogenetic profiles are now usable for the prediction of its response in breast cancer patients. This study aimed to explore the pharmacogenetic interactions among single nucleotide polymorphisms (SNPs) of genes involved in the angiogenic process and their impact on progression-free survival (PFS) and overall survival (OS) in hormone receptor-positive (HR+) metastatic breast cancer subjects administered with bevacizumab plus paclitaxel, or with paclitaxel alone (clinicaltrial.gov… More >

Shu-Yu Wu^1,2, Ching-Chia Li^3,4,5, Wen-Jeng Wu^3,4,5, Kuan-Hua Huang^6,7, Chien-Liang Liu^8,9, Shian-Shiang Wang^10,11,12, Jian-Ri Li^10,11, Han-Yu Weng¹³, Ta-Yao Tai¹³, Pi-Che Chen¹⁴, Ian-Seng Cheong¹⁴, Chung-You Tsai^15,16, Pai-Yu Cheng^15,17, Jian-Hua Hong^18,19, Chung-Hsin Chen¹⁹, Jen-Shu Tseng^20,21,22, Wun-Rong Lin^20,21, Yuan-Hong Jiang^2,23, Yu-Khun Lee^2,23, Po-Hung Lin^24,25,26, See-Tong Pang²⁴, Yung-Tai Chen²⁷, Wei-Chieh Chen²⁸, Chia-Chang Wu^29,30,31, Thomas Y. Hsueh^32,33, Hsu-Che Huang^34,35, Wei-Yu Lin^36,37,38, Chia-Cheng Yu³⁹, Jen-Kai Fang⁴⁰, Chih-Chin Yu^1,2, Yao-Chou Tsai^1,2,28,*

Canadian Journal of Urology, Vol.33, No.2, pp. 325-337, 2026, DOI:10.32604/cju.2025.069390 - 20 April 2026

Abstract Introduction: Upper urinary tract urothelial carcinoma (UTUC) is a rare malignancy, particularly in the ureter, and is associated with high rates of recurrence and metastasis. Although body mass index (BMI) has been associated with prognosis in multiple cancer types, its role as a predictive factor in UTUC is still debated. This study aimed to investigate how BMI influences survival outcomes in patients with UTUC treated with radical nephroureterectomy (RNU). Methods: This multi-center retrospective analysis by the Taiwan UTUC Collaboration Group involved 2503 patients who underwent treatment across 19 hospitals from 1988 to 2022. Patients were… More >